Publication:
Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.

dc.contributor.authorHontecillas-Prieto, Lourdes
dc.contributor.authorGarcia-Dominguez, Daniel J
dc.contributor.authorVaca, Diego Pascual
dc.contributor.authorGarcia-Mejias, Rosa
dc.contributor.authorMarcilla, David
dc.contributor.authorRamirez-Villar, Gema L
dc.contributor.authorSaez, Carmen
dc.contributor.authorde Álava, Enrique
dc.date.accessioned2023-01-25T09:42:53Z
dc.date.available2023-01-25T09:42:53Z
dc.date.issued2017
dc.description.abstractWilms tumour (WT) is the most common renal tumour in children. Most WT patients respond to chemotherapy, but subsets of tumours develop resistance to chemotherapeutic agents, which is a major obstacle in their successful treatment. Multidrug resistance transporters play a crucial role in the development of resistance in cancer due to the efflux of anticancer agents out of cells. The aim of this study was to explore several human multidrug resistance transporters in 46 WT and 40 non-neoplastic control tissues (normal kidney) from patients selected after chemotherapy treatment SIOP 93-01, SIOP 2001. Our data showed that the majority of the studied multidrug resistance transporters were downregulated or unchanged between tumours and control tissues. However, BCRP1, MDR3 and MRP1 were upregulated in tumours versus control tissues. MDR3 and MRP1 overexpression correlated with high-risk tumours (SIOP classification) (p = 0.0022 and p
dc.identifier.doi10.18632/oncotarget.14491
dc.identifier.essn1949-2553
dc.identifier.pmcPMC5355255
dc.identifier.pmid28061436
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355255/pdf
dc.identifier.unpaywallURLhttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=14491&path%5B%5D=46238
dc.identifier.urihttp://hdl.handle.net/10668/10746
dc.issue.number7
dc.journal.titleOncotarget
dc.journal.titleabbreviationOncotarget
dc.language.isoen
dc.organizationIBIS
dc.page.number11173-11186
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectMDR3
dc.subjectMRP1
dc.subjectWilms tumours
dc.subjectblastemal stratification
dc.subjectmultidrug resistance transporters
dc.subject.meshATP Binding Cassette Transporter, Subfamily B
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBiomarkers, Tumor
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshDactinomycin
dc.subject.meshDrug Resistance, Multiple
dc.subject.meshGene Expression Profiling
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshHumans
dc.subject.meshImmunoblotting
dc.subject.meshImmunohistochemistry
dc.subject.meshInfant
dc.subject.meshKidney Neoplasms
dc.subject.meshMembrane Transport Proteins
dc.subject.meshMultidrug Resistance-Associated Proteins
dc.subject.meshNephrectomy
dc.subject.meshOutcome Assessment, Health Care
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
dc.subject.meshTissue Array Analysis
dc.subject.meshVincristine
dc.subject.meshWilms Tumor
dc.titleMultidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number8
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC5355255.pdf
Size:
3.59 MB
Format:
Adobe Portable Document Format